Nintedanib is a small-molecule tyrosine kinase and inhibits platelet-derived growth factor (PDGFR), vascular endothelial growth factor (VEGFR), and fibroblast growth factor receptors (FGFR)10–12 and was developed as an anti-cancer agent for patients with non-small cell lung cancer13,14. This evidence concerns the gene PDGFRB and cancer.